SPPI Stock Sinks on Trial Update

SPPI short sellers are cheering the sell-0ff

by Josh Selway

Published on Dec 26, 2019 at 10:28 AM

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) is one of the biggest losers early on today, down 55.8% at $3.87, after the company's cancer drug poziotinib failed a mid-stage study, with the shares hitting a three-year bottom of $3.61 already as a result. This move could spark bearish analyst attention for the drugmaker, since all five covering brokerage firms came into with "strong buy" recommendations.

Looking at recent options trading, there was a near even split between call buying and put buying. Overall, call buying barely outpaced put buying by a ratio of 1.20 in the past 10 days at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), with peak open interest sitting at the January 2020 5- and 7-strike puts.

Not surprisingly, short interest is also elevated on Spectrum Pharmaceuticals, though it's short-sale restricted today due to the massive move. Based on average daily trading volumes, it'd take roughly eight sessions for SPPI short sellers to cover their bearish bets.


A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Nevada Discovery That Could Jeopardize Chinese Dominance
Click to continue to advertiser's site.
Extra Space Storage Stock Wavers After Downgrade
Raymond James downgraded to "underperform" from "market perform"
DKS to Continue Providing Benefits to Furloughed Workforce
DKS has seen an increase in put open interest over the past year
The Top Lithium Play of 2020
Click to continue to advertiser's site.